Introduction: There is controversy regarding the clinical T (cT) category of lung adenocarcinomas that manifest as part-solid nodules (PSNs). We aimed to validate the cT category and to evaluate the independent prognostic role of the nodule type (i.e., part-solid versus solid).
Introduction
Lung cancer is the greatest cause of cancer-related deaths worldwide and accounts for 15% and 8% of all cancers in men and women, respectively. 1 The incidence of early-stage lung cancer is likely to increase owing to the global aging population and the implementation of lung cancer screening programs. 2 The accurate prognostication of lung cancer, which is based on the staging system, is essential for determining appropriate therapeutic strategies, evaluating treatment results, and conveying meaningful information to patients.
T category describes the extent of a primary tumor and is one of the three components of the American Joint Commission on Cancer TNM staging system. 3 For nonmucinous lung adenocarcinomas, the eighth edition staging system's clinical T (cT) categories according to size are determined by the measurement of the solid portions of nodules on computed tomography (CT) scans, which correspond to the invasive components at microscopy for the pathologic T categorization. 4 Accordingly, the ground-glass opacity (GGO) component of part-solid nodules (PSNs) is not taken into account in cT categorization. 4 PSNs and solid nodules with equal solid portion sizes are classified within the same cT category regardless of the total tumor size or the presence of GGO.
Recently, a few studies reported the distinct prognosis of PSNs compared with that of solid nodules. [5] [6] [7] Aokage et al. 5 compared the overall survival (OS) of patients with clinical stage I, resected adenocarcinomas characterized by PSNs and solid nodules and revealed that those with PSNs had a more favorable prognosis in clinical stages IA2 and IA3. In addition, Ye et al. 6 reported the excellent prognosis of patients with resected adenocarcinomas that appeared as PSNs in clinical stage IA and reported that neither the solid portion size nor the total tumor size could predict the prognosis of PSNs. In this context, they even suggested that all PSNs should be grouped in a separate category. 6 Hattori et al. 8 proposed a similar revision of the cT category advocating that PSNs should be assigned to the "cT1a" category regardless of the solid component size. These intriguing suggestions require intensive validation using appropriate study populations and analytical methods.
The prognostic value of cT category should be analyzed in a multivariable analysis with adjustments for the important confounders. To be specific, the variables cT category, nodule type, and their interaction should be analyzed together to estimate the hazard ratio (HR) of each variable accurately. However, such an analytical approach has not been adopted in previous studies. For instance, cT category has not been used as an independent variable. [5] [6] [7] In this study, we therefore aimed to validate the prognostic value of cT category in clinical stage IA, resected lung adenocarcinomas using a multivariable analysis that included nodule type, cT category, and their interaction term. Moreover, we aimed to evaluate the independent prognostic role of nodule type (i.e., the presence of GGO) using long-term follow-up data with two distinct survival analysis methods: the Cox proportional hazard model and the mixture cure model. The former is a conventional survival analysis method used for the lung cancer staging system, and the latter enables capturing the long-term prognostic effects of the variables.
Materials and Methods
This retrospective analysis was approved by the Institutional Review Board of Seoul National University Hospital, and the requirement of written informed consent was waived.
Study Participants
We identified all adults who underwent surgical resection for lung adenocarcinomas between January 2008 and March 2014 at a single tertiary referral center. The inclusion criterion was patients with clinical stage IA (T1N0M0), resected lung adenocarcinomas with available survival records (n ¼ 861). The exclusion criteria were patients with synchronous or metachronous lung cancers (n ¼ 49) and those with mucinous adenocarcinomas (n ¼ 68). Consequently, our study comprised 744 patients (Table 1) .
Data Collection
Patients' demographics (age and sex) and clinical factors, including a history of malignancy other than lung cancer, a family history of lung cancer, smoking status (never smoked or ex-or current smoker), surgical mode (lobectomy or sublobar resection), date of preoperative CT scan, date of operation, and pathologic diagnosis were obtained from electronic medical records. For nodule characteristics, nodule location (upper lobe or other lobes) and nodule type (part-solid or solid) were obtained from radiology reports in the picture archiving and communication system. Solid portion size was measured according to the eighth edition staging system for lung cancer. 4 The longest diameter of the solid portion was measured on the lung window setting (window width, 1500 HU; level, À700 HU). All measurements were performed at the axial plane using an electronic caliper by one of the two trained radiology technicians (either M.L. with 7 y of research experience in chest CT or J.Y.J. with 1 y of research experience in chest CT) under the supervision of a board-certified thoracic radiologist (H.K. with 8 y of CT experience). The cT category (from cT1mi to cT1c) was then determined. 4 All reviewers were blinded to the pathologic diagnosis and the patient's outcome. Detailed information on the CT scan protocol is described in the Supplementary Appendix.
The primary end point was OS, which was measured from the date of operation to the date of death from any cause. Survival time was censored at April 1, 2019. Survival status and date of death were acquired from a database of the Ministry of the Interior and Safety. 9
Pathologic Diagnosis
The pathologic diagnoses of 347 of 744 patients (46.6%) were based on the 2011 lung adenocarcinoma classification described by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society 10 and were determined by the board-certified attending pathologists of our hospital as a part of their routine clinical practice. For the rest of the study population, diagnoses were established before the implementation of the 2011 adenocarcinoma classification.
Statistical Analysis
Continuous variables were presented as medians with interquartile ranges (IQRs) after testing normality, and categoric variables were described as frequencies with percentages. Participants' characteristics were compared between those with PSNs and those with solid nodules using the Mann-Whitney U test, chi-square test, or Fisher's exact test, as appropriate.
To investigate the prognostic implication of nodule type (i.e., the presence of a GGO component), log-rank test was conducted between the patients with PSNs and those with solid nodules. First, an unadjusted log-rank test was performed, and then an adjusted logrank test was conducted on the basis of inverse probability weighting. Inverse probability weighting was calculated using a logistic regression with age, sex, history of malignancy other than lung cancer, family history of lung cancer, smoking status, nodule location, surgical mode, and cT category as inputs.
To calculate the multivariable-adjusted HRs of cT category and nodule type, a multivariable Cox regression analysis was performed using covariates identical to those used for the adjusted log-rank test. In addition, the interaction term between the cT category and nodule type was analyzed. Covariates were selected on the basis of a priori knowledge of the prognostic factors of lung cancer. 11 That is, a variable selection procedure was not performed in this study. The multivariable Cox regression was repeated using solid portion size instead of cT category with the other variables were fixed. In addition, a sensitivity analysis excluding subjects with cT1mi was conducted as there were no patients with solid nodules in this category, and a subgroup analysis was performed for patients with PSNs. Cox regression analysis was conducted to validate the cT categorization system as this method was used for the development of the eighth edition staging system for lung cancer. 12 The association between the covariates and the longterm survival of patients was then assessed using a mixture cure model. 13 Cox regression analysis is based on the assumption that an event will eventually occur and that the survival curve will eventually decrease to zero. 14 However, a plateau may be visualized for survival curve after long-term follow-up, and this indicates the presence of cured subjects. [14] [15] [16] This is particularly true for patients with early-stage, resected lung adenocarcinomas. Given the long-term censored survival time of patients with clinical stage IA, resected adenocarcinomas, it was deemed reasonable to apply the cure model to these patients. The cure model can capture the relationship between the covariates and long-term survivorship, 15 and it has been applied to oncology patients with various pathologic conditions for whom a cure is statistically plausible. [16] [17] [18] The covariates used in the mixture cure model were identical to those used in the Cox regression analysis. Cure fraction, which is the probability of being cured, was estimated for each nodule type. A sensitivity analysis that excluded subjects with cT1mi was conducted.
All statistical analyses were performed using the R software, version 3.5.1 (http://www.R-project.org; package: smcure, survival, and survminer). Data imputation was not performed for missing values. A p value of less than 0.05 was considered statistically significant.
Results

Patient and Nodule Characteristics
Of the 744 patients, 362 patients (215 women) had PSNs and 382 patients (205 women; p ¼ 0.121) had solid nodules. The patients with PSNs were younger (median age, 61 y; IQR: 55-69 y) than those with solid nodules (median age, 64 y; IQR: 55-71 y; p ¼ 0.009) and were more likely to have never smoked (68.3% versus 57.2%; p ¼ 0.002). Sublobar resections had been performed more frequently for PSNs than solid nodules (19.9% versus 12.8%; p ¼ 0.010). PSNs had smaller solid portions than solid nodules (1.1 [IQR: 0.7-1.6] cm versus 2.0 [IQR: 1.5-2.5] cm; p < 0.001) and thus had earlier cT categories (proportion of cT1a: 34.3% versus 4.7%; p < 0.001). The median follow-up duration was 2463 (IQR: 2080-2998) days for PSNs and 2543 (IQR: 2062-3124) days for solid nodules (p ¼ 0.729).
For solid nodules, the 5-year OS rates were 94.4% (95% confidence interval [CI]: 84.4%-100%) for cT1a, 92.3% (95% CI: 88.4%-96.4%) for cT1b, and 79.0% (95% CI: 73.4%-84.9%) for cT1c. For PSNs, the 5-year OS rates were 97.6% (95% CI: 93.0%-100%) for cT1mi, 96.8% (95% CI: 93.7%-99.9%) for cT1a, 92.0% (95% CI: 87.9%-96.3%) for cT1b, and 85.7% (95% CI: 74.9%-98.1%) for cT1c.
Comparison of OS Between Patients With PSNs and Those With Solid Nodules
The unadjusted log-rank test between PSNs and solid nodules revealed a significant difference in OS (p < 0.001). However, this difference turned out to be insignificant (p ¼ 0.189) after adjustment for several prognostic confounders (Fig. 1 ).
Multivariable Cox Regression Analysis for OS
The multivariable-adjusted HR of the nodule type was not statistically significant (HR, 1.30; 95% CI: 0.80-2.10; p ¼ 0.291). However, the cT categories were significantly associated with OS (HR of cT1b, 2.33 [95% CI: 1.07-5.06; p ¼ 0.033]; HR of cT1c, 5.74 [95% CI: 2.51-13.12; p < 0.001]; Fig. 2 ). When solid portion size was used as one of the inputs in the Cox regression model instead of cT category, the HR of nodule type was again not significant (HR, 1.26; 95% CI: 0.78-2.03; p ¼ 0.344). Solid portion size was a significant predictor of OS (HR, 1.10; 95% CI: 1.06-1.14; p < 0.001). Other significant covariates were age, sex, history of malignancy other than lung cancer, and surgical mode in both the Cox regression models (i.e., the models with cT category or solid portion size; all p < 0.05; Tables 2 and  3 ). The interaction terms between the nodule type and cT categories and between the nodule type and solid portion size were not significant (all p > 0.05) and thus were not included in the regression models. Similar results were obtained from the sensitivity analysis except that the HR of cT1b was not significant (p ¼ 0.109; Supplementary Table 1 ).
For the PSN subgroup, the multivariable-adjusted HR of cT category was significant for cT1c (HR, 4.95; 95% CI: 1.54-15.93; p ¼ 0.007); however, the HR of cT1b was not significant (HR, 2.21; 95% CI: 0.87-5.66; p ¼ 0.097; Supplementary Table 2 ). Solid portion size was an independent prognostic factor (HR, 1.08; 95% CI: 1.02-1.14; p ¼ 0.009) when analyzed instead of the cT category ( Supplementary Table 3 ).
Multivariable Mixture Cure Model for Long-Term Survivors
The multivariable mixture cure model revealed that the cure fraction was 93.6% (IQR: 86.4%-96.7%) for patients with PSNs and 74.1% (IQR: 53.6%-88.6%) for patients with solid nodules (Table 4 ). That is, the nodule type was significantly associated with long-term survival. Solid nodules were associated with a decreased probability of being a long-term survivor (adjusted OR ¼ 0.40, 95% CI: 0.19-0.84, p ¼ 0.016). Moreover, cT1c was a negative predictor of long-term survival (OR ¼ 0.26, 95% CI: 0.07-0.93, p ¼ 0.038); however, the OR of cT1b was not statistically significant (OR ¼ 0.60, 95% CI: 0.18-2.01, p ¼ 0.407). In addition, age (OR ¼ 0.94, 95% CI: 0.90-0.97, p ¼ 0.001) and male sex (OR ¼ 0.22, 95% CI: 0.08-0.58, p ¼ 0.002) were negatively associated with long-term survival. Notably, nodule type (OR ¼ 0.42, 95% CI: 0.19-0.93, p ¼ 0.033) was consistently a significant factor associated with long-term survival when solid portion size (OR ¼ 0.92, 95% CI: 0.87-0.98, p ¼ 0.008) was used instead of the cT category (Supplementary Table 4 ). The results did not alter after the exclusion of patients with cT1mi (Supplementary Table 5 ).
Discussion
In this study, we validated that the cT category was a significant prognostic indicator of OS after adjusting for nodule type. Interestingly, nodule type was not an independent prognostic factor, and the interaction between the cT category and nodule type was not statistically significant. Moreover, cT1c and solid portion size were independent prognostic factors in the PSN subgroup. On the contrary, we exhibited that PSNs were associated with long-term survival after adjusting for conventional prognostic factors, including the cT category or solid portion size. Such relationship between nodule type and long-term survivorship could be disclosed using the mixture cure model, which is an appropriate analysis method for populations with longterm censored survival.
Given the studies reported to date, 5-7 two questions arise: (1) is the current cT categorization system suitable for PSNs? and (2) is there any interaction between the nodule type and the cT category or between the nodule type and the solid portion size? These important questions should be handled with appropriate analytical methods that consider multiple important prognostic confounders. In this study, we validated the prognostic potential of the eighth edition cT category with longterm follow-up data using the Cox regression model and the mixture cure model. The cT category or solid portion size in a continuous form were powerful prognostic indicators in clinical stage IA, resected adenocarcinomas, and no significant interactions were observed between the nodule type and cT category and between the nodule type and solid portion size. The multivariable-adjusted HR of the nodule type was not significant. Moreover, the cT category and solid portion size were validated in the PSN subgroup. Importantly, our study dealt with preoperatively obtainable factors that conformed with the purpose of clinical staging. We therefore believe that our results support the use of the current cT category for both PSNs and solid nodules. The OS of patients with PSNs was distinct according to the solid portion size and cT category (i.e., cT1a versus cT1c), and the cumulative survival was not significantly different between patients with PSNs and those with solid nodules. Aokage et al. 5 found that the survival curves between patients with PSNs and those with solid nodules were clearly separate at clinical stages IA2 and IA3. The cumulative survival of the solid nodule group dropped substantially from the very early postoperative period, which led to significant differences in OS (p < 0.01). Nevertheless, this tendency was not observed in our study. There was a considerable overlap of the survival curves between patients with PSNs and those with solid nodules in the early postoperative period. Consequently, the survival statistics obtained from the Cox proportional hazard model and the adjusted log-rank test indicated that nodule type was not associated with OS. The separation of PSNs as a distinct cT category regardless of the solid portion size was therefore not evidence based as of the time of the current study. Notwithstanding the staging system, which should consider both the short-and long-term prognostic effects of the staging variable, long-term survivorship can be evaluated separately. In our study, the results of the adjusted log-rank test between PSNs and solid nodules were not statistically significant. Nevertheless, the underlying assumption of the log-rank test that censoring is unrelated to prognosis may not be appropriate for the analysis of the long-term survival fraction of patients with clinical stage IA adenocarcinomas. 19 A different approach, the mixture cure model, was thus employed in this study to investigate the long-term prognostic potential of nodule type. Our study results, which partly coincide with those of past studies, 6, 7 reported that the nodule type (i.e., PSN) could be used as a long-term prognostic indicator for surgical candidates with clinical stage IA adenocarcinomas. One may argue that the solid portion size would be different between PSNs and solid nodules even in the same cT category and that such discrepancy would be the potential confounder. However, after adjustment for solid portion size, PSNs were still associated with long-term survival.
Our study had limitations. First, there were a small number of patients with PSNs with cT1c and those with solid nodules with cT1a. Second, pathologic stage and histologic subtype were not analyzed in our study. However, our study specifically focused on the prognostic value of the clinical staging variables. It should be noted that the prognostic value of the clinical staging system should be investigated on the basis of preoperatively obtainable factors. That is, all predictors need to be available when the prediction system (i.e., clinical staging system) is intended to be used. 20 Third, CT acquisition protocols including radiation dosage and reconstruction slice thickness were heterogeneous in our study. It is known that nodule type classification is vulnerable to observer variability. 21 The heterogeneity in CT acquisition may have a negative impact on accurate nodule classification. However, recent studies have reported that nodule classification and solid portion measurement are not substantially affected by CT protocols. 22, 23 In this context, a large prospective study with uniform CT protocols and reproducible measurement tools (e.g., deep learning-based segmentation and quantification) is warranted. Fourth, the nodule type was primarily obtained from radiologic reports. Although all nodules were reviewed during the measurement process and misreadings were corrected, the retrospective nature of our study cannot be free from bias and observer variability. Fifth, our study population comprised a single ethnic group, and it has been reported that the proportion of adenocarcinomas in NSCLC and the prevalence of EGFR mutations are higher in Asian populations than in Caucasians. 24, 25 Therefore, care should be taken while evaluating PSNs in different ethnic groups, and the potential discrepancy in OS should be noted. In conclusion, the eighth edition cT categorization system is valid for lung adenocarcinomas manifesting as PSNs and solid nodules. The need to classify PSNs in a single category regardless of the solid component size was not confirmed in our study. Nevertheless, PSNs are a prognostic factor associated with long-term survival. Validation of our observations in a prospective cohort study is warranted.
